Know Cancer

or
forgot password

Immunobiology of Cancer


N/A
18 Years
N/A
Not Enrolling
Both
Neoplasms

Thank you

Trial Information

Immunobiology of Cancer


BACKGROUND

We have previously demonstrated that tumor-specific T cells could be identified in >50% of
patients with metastatic melanoma and these cells appeared to be rendered anergic in vivo
[Nature Medicine 5:677, 1999]. Recently we discovered that there is a signaling defect in
the Interferon (IFN) pathway in immune cells from melanoma patients [PLOS Medicine 4:897
2007]. Interestingly, preliminary studies are showing the same defect in immune cells from
breast cancer patients (unpublished). We would like to expand our research to all types of
cancer to determine whether these phenomena occur in different cancer types.

OBJECTIVES

Our primary objective is to determine whether there is an IFN signaling defect in different
types of cancers and to determine what is causing this defect.

The second objective is to determine whether these PBMCs are rendered anergic.

INVESTIGATIONAL PLAN

The study population will consist of patients who have been diagnosed with cancer,
regardless of sex or ethnicity. Blood will be collected during the subjects regularly
scheduled laboratory appointment and peripheral blood mononuclear cells (PBMCs) will be
isolated for research purposes. These PBMCs will undergo studies, i.e. phosflow, qPCR,
proliferation, survival, etc., to determine immune responses for T cells (CD4 and CD8), B
cells (CD19), natural killer cells (CD16), and possibly monocytes (CD14).


Inclusion Criteria:

Participants who have cancer or participants who do not have cancer
and/or an autoimmune disorder and are age 18 or over.

Exclusion Criteria:Participants who have an autoimmune disorder and/or are under the age
of 18 years.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Peter P Lee

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

VAR0033

NCT ID:

NCT00767533

Start Date:

October 2008

Completion Date:

October 2011

Related Keywords:

  • Neoplasms
  • Neoplasms

Name

Location

Stanford University School of Medicine Stanford, California  94305-5317